Precigen Inc PGEN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PGEN is a good fit for your portfolio.
News
-
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
-
Actym Therapeutics Appoints Thomas Smart as CEO
-
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
-
Precigen Reports Full Year 2023 Financial Results and Business Updates
-
Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
-
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th
-
Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
-
Precigen Gets FDA Breakthrough Therapy Designation for AdenoVerse
Trading Information
- Previous Close Price
- $1.40
- Day Range
- $1.39–1.44
- 52-Week Range
- $0.84–1.88
- Bid/Ask
- $1.40 / $1.41
- Market Cap
- $350.98 Mil
- Volume/Avg
- 413,594 / 981,049
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 55.39
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 202
- Website
- http://www.precigen.com
Comparables
Valuation
|
Metric
|
PGEN
|
JANX
|
PTGX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.96 | 6.37 | 4.31 |
Price/Sales | 55.39 | 258.06 | 23.79 |
Price/Cash Flow | — | — | — |
Price/Earnings
PGEN
JANX
PTGX
Financial Strength
|
Metric
|
PGEN
|
JANX
|
PTGX
|
|---|---|---|---|
Quick Ratio | 2.80 | 26.40 | 16.54 |
Current Ratio | 2.99 | 26.80 | 16.71 |
Interest Coverage | −211.82 | — | — |
Quick Ratio
PGEN
JANX
PTGX
Profitability
|
Metric
|
PGEN
|
JANX
|
PTGX
|
|---|---|---|---|
Return on Assets (Normalized) | −37.21% | −10.49% | −16.60% |
Return on Equity (Normalized) | −50.43% | −11.78% | −18.20% |
Return on Invested Capital (Normalized) | −46.33% | −15.13% | −23.45% |
Return on Assets
PGEN
JANX
PTGX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Gvnypwlnsp | Gbvp | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zlcnsghd | Kkkfdjn | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jdxmwtmvy | Jjdwwp | $97.8 Bil | |
MRNA
| Moderna Inc | Xtwzcwk | Npy | $41.3 Bil | |
ARGX
| argenx SE ADR | Dtlcshf | Vwzt | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Sdgsvsz | Ddpvh | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Chptzcgn | Twjwggn | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ldpwyldl | Fryrwb | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Hxrfwqszb | Pdvnqf | $12.5 Bil | |
INCY
| Incyte Corp | Jphzzsmxy | Vdhbdt | $11.6 Bil |